This is not an official government website.
Copyright © 2026 PLEJ LC. All rights reserved.
Read twice and referred to the Committee on Finance.
Introduced June 12, 2025 by Richard Blumenthal · Last progress 8 months ago
Removes cost barriers for evidence-based opioid treatment by: (1) launching a Medicare model that eliminates coinsurance, copays, and deductibles for certain opioid treatments and recovery supports in 15 qualifying States; (2) requiring group health plans and individual market insurers to cover specified opioid treatments with no cost-sharing for plan years starting on or after January 1, 2027; and (3) boosting federal Medicaid support by setting a 90% FMAP for states’ medication-assisted treatment spending from enactment and allowing states to optionally include recovery support services (peer counseling, transportation) as part of that treatment benefit. The Medicare model is protected from routine termination/modification for its first five years to provide stability during implementation.